In light of the strong desire to shorten timelines and lower cost for biologics such as monoclonals specially biosimilars, and address surging demand for complex proteins such as bispecific antibodies ...

WuXiUI™ ultra-intensified fed-batch platform offers a new process option for maximum flexibility to meet various clients' needs in biologics development and manufacture. The platform can significantly ...

REDWOOD CITY, Calif.--(BUSINESS WIRE)-- C3 AI (NYSE: AI), the Enterprise AI application software company, today announced that Genentech, the medical biotechnology company, has selected C3 AI ...

Before the advent of biologics, commercialization of a therapeutic relied on successfully scaling up to meet market demand. This scaling-up strategy expanded biomanufacturing capacity by upsizing the ...

This press release contains “forward-looking statements” pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. (“we,” “our” or the ...

ADMA Biologics receives FDA approval for a process enhancing plasma production yields by 20%, boosting growth and capacity for its products. ADMA Biologics, Inc. has announced the U.S. FDA approval of ...

Process Raman spectroscopy is a commonly used tool for real-time monitoring and control in bioprocessing. This article outlines the role of cultured cells in biologics manufacturing and why developing ...

As global uncertainty grows, biotech and biopharma companies are rethinking manufacturing strategies to reduce risk and ensure continuity. Onshoring drug substance development for biologics offers a ...

Amid a spate of high-profile investments in U.S. pharmaceutical production, two contract manufacturers are getting in on the action with an emphasis on biologic drugs. First, active pharmaceutical ...

WuXi Biologics ('WuXi Bio') (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has won six prestigious awards and two individual ...

DUBLIN--(BUSINESS WIRE)--The "Digital Biomanufacturing Market Industry Trends and Global Forecasts to 2035, by Type of Technology, Deployment Options, Type of Biologics and Key Geographical Regions" ...

OKLAHOMA CITY--(BUSINESS WIRE)--Cytovance Biologics today announced a growth equity investment of $22.5 million from Great Point Partners, LLC, a Greenwich, Connecticut private investment firm focused ...